Product Description
GMA301 is a humanized monoclonal antibody against endothelin receptor A, may become the first long-lasting PAH drug with better efficacy and less adverse effects. (Sourced from: https://www.gmaxbiopharm.com/wap_product_detailen/id/4.html)
Mechanisms of Action: ETa Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gmax Biopharm
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Hypertension, Pulmonary
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20200854 | P1 |
Not yet recruiting |
Hypertension, Pulmonary |
None |